Psoriasis epidemiology and demographics

Revision as of 20:00, 10 April 2013 by Sapan Patel (talk | contribs)
Jump to navigation Jump to search

Psoriasis Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Psoriasis from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

X-ray

Ultrasound

CT scan

MRI

Other Imaging Studies

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Psoriasis epidemiology and demographics On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Psoriasis epidemiology and demographics

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Psoriasis epidemiology and demographics

CDC on Psoriasis epidemiology and demographics

Psoriasis epidemiology and demographics in the news

Blogs on Psoriasis epidemiology and demographics

Directions to Hospitals Treating Psoriasis

Risk calculators and risk factors for Psoriasis epidemiology and demographics

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Please help WikiDoc by adding more content here. It's easy! Click here to learn about editing.

Epidemiology and Demographics

Prevalence

The prevalence of psoriasis in Western populations is estimated to be around 2-3%.

Age

Onset before age 40 usually indicates a greater genetic susceptibility and a more severe or recurrent course of psoriasis.

Gender

Psoriasis affects both sexes equally and can occur at any age, although it most commonly appears for the first time between the ages of 15 and 25 years.

Developed Countries

A survey [2] conducted by the National Psoriasis Foundation (a US based psoriasis education and advocacy group, which is partly funded by pharmaceutical companies) found a prevalence of 2.1% among adult Americans. The study also found that 35% of people with psoriasis could be classified as having moderate to severe psoriasis.

References

Template:WH Template:WS